Inefficient mitochondrial apoptosis is a key determinant in therapeutic success of a number of anticancer regimens. Mitochondrial apoptosis is tightly controlled by the Bcl-2 protein family. Bcl-2 ...

Bionano Genomics, Inc. today announced the Stratys ™ system for high throughput optical genome mapping (OGM) and VIA ™ software for visualization, interpretation and reporting of genome analysis for ...

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

ABBOTT PARK, Ill., June 14, 2017 — Abbott announced today that the Alinity hq analyzer for hematology is now CE Marked and available in Europe and other countries that recognize CE Mark. The analyzer ...

Please provide your email address to receive an email when new articles are posted on . Researchers from Europe and the U.S. developed a hematologic toxicity score that can predict which patients are ...

AUBURN — Abbott, an international medical device and health care products manufacturer, chose to unveil its newest technology at Auburn Community Hospital. Auburn is the first hospital in the U.S.

HORIBA UK Ltd, Medical announces the first global installation of its new HELO high throughput fully automated hematology platform in Torbay Hospital. The Laboratory there has achieved UKAS ISO 15189 ...

Engineering researchers at University of California, San Diego, developed a remote-controlled cancer immunotherapy system. The ultrasound-based system is designed to noninvasively control genetic ...

Leveraging Mobile Technology to Improve Efficiency of the Consent-to-Treatment Process Microbiology indicators and antifungal drug–dispensing data were extracted from hospital information systems at ...

We did a secondary analysis of six multicenter studies enrolling patients with hematologic malignancies. FT was evaluated using the financial difficulties item of the European Organisation for ...

Morristown, N.J.-based Atlantic Health System named Mohamad Cherry, MD, medical director of its hematology and cellular therapy programs, it said Feb. 23. Dr. Cherry joined the system in 2017, where ...